title: Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.
abstract: OBJECTIVE
  This study was done in order to investigate the effect of CYP2C19 genetic polymorphism on the cure rate of children who received proton pump inhibitors (PPI)-based triple therapy for treating Helicobacter pylori (H. pylori) infection.
  
  
  METHODS
  Participants included 100 children with H. pylori-positive gastritis diagnosed by endoscopy and biopsy in addition to H. pylori stool antigen test. Cure rate was assessed after 1 month of completion of a triple treatment course for 14 days. CYP2C19 polymorphism was analyzed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
  
  
  RESULTS
  Results showed that cases with a CYP2C19 genotypic status consistent with the heterozygote extensive metabolizers (HetEMs) had a higher cure rate of H. pylori when compared with the homozygote extensive metabolizers (HomEMs) although it was statistically nonsignificant (84.6 vs. 69.2). In addition, the poor metabolizers (PMs) had a higher cure rate compared with those of the HomEMs which was also statistically nonsignificant (77.8 vs. 69.2). The cure rate was also higher among both the groups of HetEMs and PMs combined together compared to the HomEMs (OR = 2.15, p > 0.05). Comparing cases regarding their age, gender, and severity of H. pylori gastritis revealed a better cure rate in the age group >10 years, in females and in mild and moderate cases than other cases although statistically nonsignificant.
  
  
  CONCLUSIONS
  The higher cure rate of H. pylori infection using the triple therapy for 2 weeks among HetEMs and PMs cases compared to the HomEMs might warrant a need for a therapy augmentation or modification for the HomEMs.
authors.affiliation: Genetics Unit, Mansoura University, Mansoura, Egypt, settin60@gmail.com.
authors.forename: Ahmad
authors.initials: A
authors.lastname: Settin
authors.forename: Ahmad Fathy
authors.initials: AF
authors.lastname: Abdalla
authors.forename: Ayman S
authors.initials: AS
authors.lastname: Al-Hussaini
authors.forename: Rizk
authors.initials: R
authors.lastname: El-Baz
authors.forename: Amr
authors.initials: A
authors.lastname: Galal
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage; D002648:Child; D017291:Clarithromycin / Q000008:administration & dosage; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D005260:Female; D005756:Gastritis / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000382:microbiology*; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole / Q000008:administration & dosage; D008297:Male; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D054328:Proton Pump Inhibitors / Q000008:administration & dosage; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D000658:Amoxicillin; D065731:Cytochrome P-450 CYP2C19; D017291:Clarithromycin